Novartis to finally shed its stake in Roche

4 November 2021
swiss-flag-big

Novartis (NOVN: VX) has agreed to sell 53.3 million (around 33%) bearer shares of fellow Swiss pharma giant Roche (ROG SIX) in a bilateral transaction to Roche for a total consideration of $20.7 billion, with the news sending the latter’s shares up more than 3% to $425.60 Swiss francs, while Novartis was hardly changed.

Vas Narasimhan, chief executive of Novartis, said: “After more than 20 years as a shareholder of Roche, we concluded that now is the right time to monetize our investment. Today’s announcement is consistent with our strategic focus and we intend to deploy the proceeds from the transaction in line with our capital allocation priorities to maximize shareholder value and continue to reimagine medicine.”

Dr Narasimhan has sought to refocus Novartis since taking the top position in 2018, spinning off its eye-care unit Alcon and last week outlining a strategic review of Sandoz, its generics and biosimilars business, including a divestment of the unit.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical